Drug-induced arrhythmia: pharmacogenomic prescribing?
Author(s) -
Elijah R. Behr,
Dan M. Roden
Publication year - 2012
Publication title -
european heart journal
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 4.336
H-Index - 293
eISSN - 1522-9645
pISSN - 0195-668X
DOI - 10.1093/eurheartj/ehs351
Subject(s) - medicine , torsades de pointes , pharmacogenomics , formulary , drug , medical prescription , intensive care medicine , pharmacogenetics , qt interval , adverse drug event , adverse effect , pharmacology , biochemistry , chemistry , genotype , gene
Drug-induced Torsades de Pointes is a rare, unpredictable, and life-threatening serious adverse event. It can be caused by both cardiac and non-cardiac drugs and has become a major issue in novel drug development and for the regulatory authorities. This review describes the problem, predisposing factors, and the underlying genetic predisposition as it is understood currently. The future potential for pharmacogenomic-guided and personalized prescription to prevent drug-induced Torsades de Pointes is discussed. Database searches utilized reports from www.qtdrugs.org up to January 2012, case reports and articles from www.pubmed.com up to January 2012, and the British National Formulary edition at www.bnf.org.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom